Related links
214787Orig1s000 SUMMARY REVIEW - accessdata.fda.gov
Oct 21, 2020 The overall benefit-risk profile of RDV is favorable to support an indication for adults and pediatric patients (12 years and older and weighing
Learn more
Risk Assessment and Risk Mitigation Review(s)
Aug 16, 2019 This review by the Division of Risk Management (DRISK) evaluates whether a risk evaluation and mitigation.
Learn more
FDA Risk Evaluation and Mitigation Strategies (REMS)
by A Dabrowska 2018 Cited by 10 FDAs determination that a drug is safe does not signify an absence of risk but rather that the drugs clinical benefits outweigh its known and
Learn more